While sparking excitement among biopharma companies focused on rare and ultrarare indications, experts say FDA Commissioner ...

Sponsored communities reduce timelines and increase relevance. Digital engagement allows for rapid study launches and ...

The FDA and NIH recently announced plans to phase out animal testing requirements for some therapies. While organoid and AI ...

While the Trump administration has painted the jettisoning of staff and regulations as good for business, there are multiple ...

Since Elevidys' accelerated approval in 2023, experts have been clamoring for more data, particularly in older and ...

President Donald Trump unwrapped a massive drug pricing policy as CMS prepares for the next round of Medicare drug price ...

The star of the acquisition is the enzyme replacement therapy INZ-701, being developed for the rare disease ENPP1 deficiency.

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

Lilly will use Rznomics’ proprietary ribozyme technology to develop RNA editing therapies for congenital hearing loss.

Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...

Over Lars Fruergaard Jørgensen's eight years as CEO, Novo’s sales, profits and share price have almost tripled, the company ...

The FDA also approved the use of Zynyz as a monotherapy for patients with squamous cell carcinoma of the anal canal who are ...